OPEN END TURBO BULL OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 03:41:57 2024-06-11 pm EDT | ||
| 16.46 EUR | -1.02% |
|
| Current month | +18.76% | ||
| 1 month | +48.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-11 | 16.46 | -1.02% |
| 24-06-10 | 16.63 | +0.18% |
| 24-06-07 | 16.6 | +0.48% |
| 24-06-06 | 16.52 | +0.73% |
| 24-06-05 | 16.4 | +4.66% |
Real-time BOERSE MUENCHEN
Last update June 11, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC3NX4 |
| ISIN | DE000HC3NX41 |
| Date issued | 2023-01-30 |
| Strike | 305.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.63 € |
|---|---|
| Lowest since issue | 1.65 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
481.5
USD
Average target price
463.4
USD
Spread / Average Target
-3.76%
- Stock Market
- Certificates
- Certificat
